耳鼻咽喉科・頭頸部外科93巻7号

2021年06月発行

特集 必見！頭頸部がんのあたらしい治療 《あたらしい薬物療法》

免疫チェックポイント阻害薬—現状と今後の展開

著者： 岡弘毅¹ 本間義崇¹

所属機関： ¹国立がん研究センター中央病院頭頸部内科

ページ範囲：P.500 - P.505

POINT

●頭頸部癌に対してもニボルマブとペムブロリズマブが保険適応になった。

●再発または遠隔転移を有する頭頸部扁平上皮癌に対する免疫チェックポイント阻害薬の現状について概説する。

●局所進行頭頸部扁平上皮癌と，再発または遠隔転移を有する頭頸部扁平上皮癌に対する治療開発の状況について概説する。

参考文献

1）Ferris RL, et al：Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375：1856-1867, 2016

2）Ferris RL, et al：Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck：2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 81：45-51, 2018

3）日本臨床腫瘍学会（編）：頭頸部がん薬物療法ガイダンス 第2版．金原出版，東京，2018

4）Chow LQM, et al：Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma：results from the phase Ⅰb KEYNOTE-012 expansion cohort. J Clin Oncol 34：3838-3845, 2016

5）Vermorken JB, et al：Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359：1116-1127, 2008

6）Maurer W, et al：Multiple testing in group sequential trials using graphical approaches. Stat Biopharm Res 5：311-320, 2013

7）Burtness B, et al：Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck（KEYNOTE-048）：a randomised, open-label, phase 3 study. Lancet 394：1915-1928, 2019

8）Ferris RL, et al：Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma：EAGLE, a randomized, open-label phase Ⅲ study. Ann Oncol 31：942-950, 2020

9）Colevas AD, et al：Safety and clinical activity of atezolizumab in head and neck cancer：results from a phase Ⅰ trial. Ann Oncol 29：2247-2253, 2018

10）Bristol-Myers Squibb：Press release. Bristol-Myers Squibb reports first quarter financial results　https://news.bms.com/news/corporate-financial/2019/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results（2020/01/17参照）

11）Massarelli E, et al：INDUCE-1：Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor（ICOS）agonist GSK3359609（GSK609）with platinum＋5-FU chemotherapy（5-FU/plat）, with or without pembrolizumab（PE）, for the treatment of advanced solid tumors. J Clin Oncol 38（suppl）：6544, 2020

12）Ott PA, et al：Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma：an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol 5：202, 2015

13）Taylor MH, et al：Phase ⅠB/Ⅱ trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol 38：1154-1563, 2020

14）Uppaluri R, et al：Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer：a multicenter, phase Ⅱ trial. Clin Cancer Res 26：5140-5152, 2020

15）Schoenfeld JD, et al：Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma：a phase 2 open-label randomized clinical trial. JAMA Oncol 6：1563-1570, 2020

16）Zinner R, et al：Neoadjuvant nivolumab（N）plus weekly carboplatin（C）and paclitaxel（P）in resectable locally advanced head and neck cancer. J Clin Oncol 38（suppl）：6583, 2020

17）Hecht M, et al：A multicenter phase Ⅱ trial of the combination cisplatin/docetaxel/durvalumab/tremelimumab as single-cycle induction treatment in locally advanced HNSCC（CheckRad-CD8 trial）. J Clin Oncol 38（suppl）：6519, 2020

18）Cohen EE, et al：Primary results of the phase Ⅲ JAVELIN head & neck 100 trial：avelumab plus chemoradiotherapy（CRT）followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck（LA SCCHN）. Ann Oncol 31（suppl 4）：S658, 2020

19）Bourhis J, et al：Pembrolizumab versus cetuximab, concomitant with radiotherapy（RT）in locally advanced head and neck squamous cell carcinoma（LA-HNSCC）：results of the GORTEC 2015-01“PembroRad”randomized trial. Ann Oncol 31（suppl 4）：S1168, 2020